Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104671 | 0.90 | MEN1 (0.37) | NPBWR1MAPTMCHR1POLBBUB1 | |
| SCHEMBL3114532 | 0.90 | NR3C1 (0.37) | NPBWR1MCHR1 | |
| SCHEMBL1944519 | 0.87 | AXL (0.38) | MAPTHDAC1POLBBUB1CSF1R | |
| SCHEMBL4872209 | 0.87 | JAK2 (0.38) | MCHR1MEN1KMT2A | |
| SCHEMBL3112648 | 0.85 | MAPT (0.35) | NPBWR1MAPTMEN1KMT2A | |
| SCHEMBL25245155 | 0.84 | BTK (0.36) | NPBWR1MAPTMCHR1POLBCSF1R | |
| SCHEMBL30406047 | 0.84 | BTK (0.36) | NPBWR1MAPTMCHR1POLBCSF1R | |
| SCHEMBL3108627 | 0.82 | CYP1A2 (0.39) | MAPT | |
| SCHEMBL30310266 | 0.81 | BTK (0.44) | NPBWR1MAPTMCHR1POLB | |
| SCHEMBL3112384 | 0.81 | JAK2 (0.40) | MCHR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2001880-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | NPBWR1 863/4885MAPT 538/4885HDAC1 2198/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | NPBWR1 863/4885MAPT 538/4885HDAC1 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.